LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Amgen Inc

Fermé

SecteurSoins de santé

290.17 1.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

289.48

Max

290.72

Chiffres clés

By Trading Economics

Revenu

1.1B

1.7B

Ventes

-937M

8.1B

P/E

Moyenne du Secteur

26.32

51.198

BPA

4.9

Rendement du dividende

3.3

Marge bénéficiaire

21.23

Employés

28,000

EBITDA

-1.7B

1.2B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+12.35% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.30%

2.40%

Prochains Résultats

5 août 2025

Date du Prochain Dividende

5 sept. 2025

Date du Prochain Détachement de Dividende

15 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3B

155B

Ouverture précédente

289.04

Clôture précédente

290.17

Sentiment de l'Actualité

By Acuity

39%

61%

126 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Amgen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 mai 2025, 20:17 UTC

Résultats

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 mai 2025, 16:13 UTC

Acquisitions, Fusions, Rachats

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 mai 2025, 20:01 UTC

Résultats

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 mai 2025, 20:01 UTC

Résultats

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY25 Capital Expenditures About $2.3B

1 mai 2025, 20:01 UTC

Résultats

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Repatha Sales $656M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q EVENITY Sales $442M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Adj EPS $4.90 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q EPS $3.20 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Rev $8.15B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Rev $8.1B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen 1Q EPS $3.20 >AMGN

1 mai 2025, 20:01 UTC

Résultats

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Comparaison

Variation de prix

Amgen Inc prévision

Objectif de Prix

By TipRanks

12.35% hausse

Prévisions sur 12 Mois

Moyen 326.18 USD  12.35%

Haut 400 USD

Bas 252 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

22 ratings

11

Achat

10

Maintien

1

Vente

Score Technique

By Trading Central

270.44 / 276.44Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

126 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.